表紙
市場調查報告書

阿茲海默症:流行病學的預測 (∼2028年)

Alzheimer's Disease: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 940506
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
阿茲海默症:流行病學的預測 (∼2028年) Alzheimer's Disease: Epidemiology Forecast to 2028
出版日期: 2020年05月29日內容資訊: 英文 47 Pages
簡介

全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、中國)的阿茲海默症(AD)的患病數在預測期間內預計以3.58%的年複合成長率發展,從2018年的3275萬3241人,2028年增加到4447萬3527人。該地區的診斷AD數,預計同期間中以3.54%的年複合成長率發展,從2018年的912萬848個案例,2028年增加到1234萬8971個案例。

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、中國)的阿茲海默症(AD)的罹患情形調查,疾病概要,患病人數的變化、預測,各種區分的明細等資訊。

目錄

第2章 阿茲海默症(AD):摘要整理

第3章 流行病學

  • 病的背景
  • 風險要素、並存症
  • 世界的趨勢、過程
  • 預測手法
  • 流行病學的預測
    • 整體患病人數
    • AD患病人數:性別
    • AD患病人數:各年齡
    • AD患病人數:各重症度
    • AD診斷患病人數
    • AD診斷患病人數:性別
    • AD診斷患病人數:各年齡
    • AD診斷患病人數:各重症度
    • 輕度認知障礙的患病人數
    • 輕度認知障礙的患病人數:性別
    • 輕度認知障礙的患病人數:各年齡
    • 診斷輕度認知障礙的患病人數
    • 診斷輕度認知障礙的患病人數:性別
    • 診斷輕度認知障礙的患病人數:各年齡
  • 討論

第4章 附錄

目錄
Product Code: GDHCER239-20

Alzheimer's Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of AD in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of AD. In the 8MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of AD from 32,753,241 cases in 2018 to 44,473,527 cases in 2028 at an AGR of 3.58% during the forecast period. In the 8MM, the diagnosed prevalent cases of AD will increase from 9,120,848 cases in 2018 to 12,348,971 cases in 2028 at an AGR of 3.54% during the forecast period. AD is more common in older adults. These trends are reflected in GlobalData's forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.

Scope

  • The Alzheimer's disease (AD) Epidemiology Report provides an overview of the risk factors and global trends of AD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the prevalent cases of AD (total and diagnosed) segmented by sex, age (ages ≥60 years), and severity in these markets. Additionally, this report provides a 10-year epidemiological forecast for the prevalent cases of mild cognitive impairment (MCI) (total and diagnosed) segmented by sex and age (ages ≥60 years) in these markets.
  • The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Alzheimer's Disease Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
  • Understand magnitude of AD population by severity at diagnosis.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Alzheimer's Disease: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for AD (2018-2028)
    • 3.5.1 Total Prevalent Cases of AD
    • 3.5.2 Sex-Specific Total Prevalent Cases of AD
    • 3.5.3 Age-Specific Total Prevalent Cases of AD
    • 3.5.4 Total Prevalent Cases of AD by Severity
    • 3.5.5 Diagnosed Prevalent Cases of AD
    • 3.5.6 Sex-Specific Diagnosed Prevalent Cases of AD
    • 3.5.7 Age-Specific Diagnosed Prevalent Cases of AD
    • 3.5.8 Diagnosed Prevalent Cases of AD by Severity
    • 3.5.9 Total Prevalent Cases of Mild Cognitive Impairment
    • 3.5.10 Sex-Specific Total Prevalent Cases of Mild Cognitive Impairment
    • 3.5.11 Age-Specific Total Prevalent Cases of Mild Cognitive Impairment
    • 3.5.12 Diagnosed Prevalent Cases of Mild Cognitive Impairment
    • 3.5.13 Sex-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
    • 3.5.14 Age-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - KOLs Interviewed for this Report
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for AD

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of AD, Men and Women, Ages ≥60 Years, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of AD, Men and Women, Ages ≥60 Years, 2018 and 2028
  • Figure 3: 8MM, Total Prevalence of AD (%), Men and Women, Ages ≥60 Years, 2018
  • Figure 4: 8MM, Total Prevalence of MCI, Men and Women, Ages ≥60 Years, 2018
  • Figure 5: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AD Based on the DSM-IV and Clinical Criteria
  • Figure 6: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of MCI
  • Figure 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of AD by Severity
  • Figure 8: 8MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years
  • Figure 9: 8MM, Total Prevalent Cases of AD, by Sex, Ages ≥60 Years, N, 2018
  • Figure 10: 8MM, Total Prevalent Cases of AD by Age, Both Sexes, N, 2018
  • Figure 11: 8MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 12: 8MM, Diagnosed Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 13: 8MM, Diagnosed Prevalent Cases of AD, by Sex, Ages ≥60 Years, N, 2018
  • Figure 14: 8MM, Diagnosed Prevalent Cases of AD by Age, Both Sexes, N, 2018
  • Figure 15: 8MM, Diagnosed Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 16: 8MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years
  • Figure 17: 8MM, Total Prevalent Cases of MCI, by Sex, Ages ≥60 Years, N, 2018
  • Figure 18: 8MM, Total Prevalent Cases of MCI by Age, Both Sexes, N, 2018
  • Figure 19: 8MM, Diagnosed Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years
  • Figure 20: 8MM, Diagnosed Prevalent Cases of MCI, by Sex, Ages ≥60 Years, N, 2018
  • Figure 21: 8MM, Diagnosed Prevalent Cases of MCI by Age, Both Sexes, N, 2018